Hot Investor Mandate: R&D Subsidiary of China Pharma Seeks Various Partnerships with Digital Health Technologies & Early-Stage Therapeutics Across Various Modalities

24 Oct

An R&D subsidiary of a Chinese pharmaceutical focuses on novel therapeutics. In the meantime, the firm is also responsible for sourcing global technology assets for the parent company. The firm is interested in Therapeutics and Healthcare IT opportunities. Fully funded by the parent company, the firm’s allocation size varies for the case to case, no upper limit, and in addition to investment the firm is also interested in co-development, in-licensing, and acquiring.

The firm is especially interested in Antibody therapeutics including new structure antibodies, Gene Therapy, CAR-T Therapy, Targeted Therapy, oncolytic virus therapy, and rare disease. Any combination of AI technology and therapeutics is preferred. For therapeutics, the firm focuses on products in pre-clinical and Phase I stage and will consider orphan indications.

The firm has no specific requirements for company and management team.

If you are interested in more information about this investor and other investors tracked by LSN, please email

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: